INTRODUCTION AND OBJECTIVES: Previous studies have
shown racial disparity in the epidemiology of prostate cancer (PCa) for African American (AA) men, creating a dilemma whether these men should be enrolled in active surveillance (AS). We sought to assess the risk of grade reclassification (GR) to grade group (GG) !2 and !3 in AA men, compared with a non-AA cohort, meeting the criteria for an indolent disease and otherwise ideal candidates for AS.
METHODS: Between 1995-2018, we retrospectively identified 1,312 men with GG 1 (Gleason Score [GS] 6) cancer meeting the criteria for very low risk PCa (<3 cores positive, <50% maximum cancer involvement in any positive core and PSA density [PSAD] <0.15) at diagnosis, from the Johns Hopkins AS registry. Out of 1,312 men (median follow-up 4 years ), 103 men were AA while 1209 men were non-AA (97% Caucasian). Among AA men 22% had MRI targeted biopsies compared to 21% in non-AA men. Rates of GR to GG !2 (GS !3þ4) and !3 (GS !4þ3) were evaluated using survival analysis.
RESULTS: The median number of biopsies was 3 (IQR 2-5) for both race groups and the median interval between biopsies was 45 months for AA men vs. 51 months for non-AA men (p[0.1). Thirty-one AA-men and 230 non-AA men had GR to GG !2. In men with GR, AA men were more likely to be upgraded to GG !3 compared to non-AA men (45% [14/31] vs 31% [72/230] , p[0.03). On Kaplan-Meir analysis the 2, 5 and 10-year GR free survival in AA men vs. non-AA men was 84%, 69% and 50% vs. 90%, 81% and 70%, respectively for GR to GG !2 (p[0.002), and 92%, 83% and 78% vs. 97%, 94% and 91%, respectively for GR to GG !3 (p[0.001) ( Figure) . Upon adjusting for PSAD, age and year of diagnosis, AA men remained at a significantly higher risk of GR to GG !2 (HR[1.9, 95% CI [1.3-2.8]; p[0.001) and GG !3 (HR[2.6, 95% CI [1. 4-4.7] , p[0.002) as compared to non-AA men.
CONCLUSIONS: African-American men meeting even the most stringent AS criteria have a relatively higher risk of harboring occult cancer foci of an aggressive phenotype compared to similar nonAfrican-American men. Offering AS to these men should be approached with greater caution and, if enrolled, AA men should be closely followed. is a well-established option for men diagnosed with early prostate cancer. There is however no consensus on the ideal inclusion and exclusion criteria, i.e. what defines disease that is unsafe to monitor, or how to optimally survey men. Here we tested whether using prognosis can guide a rational approach to AS.
METHODS: We have previously developed and validated the 5 tiered-Cambridge Prognostics Groups (CPG) that predicts disease prognosis at diagnosis (Gnanapragasam et al 2018 doi: 10.1186/ s12916-018-1019-5). The first 3 groups (CPG1-3) were of interest in this study defined as:
CPG1: Grade Group (GG) 1 AND PSA<10 AND Stages T1 to T2, CPG2: GG 2 OR PSA 10 to 20 AND Stages T1 to T2, CPG3: GG2 AND PSA 10 to 20 ng/ml AND Stages T1 to T2 OR GG3 AND Stages T1 to T2.
These strata map closely to the new AUA low, favourable and unfavourable intermediate-risk groups respectively. The model was applied to UK and Swedish historical cohorts to test differences in 10-year prostate cancer mortality (PCM) in men managed conservatively or by upfront radical therapy. We then applied the model to a contemporary mpMRI biopsy diagnosed and monitored AS cohort to identify predictors of pathological progression.
RESULTS: The UK cohort (n[3,659) included 1,299, 1,413 and 947 men in CPG1, 2 and 3 respectively. The cumulative PCM in CPG1 was 2.3%. The corresponding rates for treated and untreated men was 1.5% & 3.5% in CPG2 and 1.9% & 8.6% in CPG3. Similar results were seen in a Swedish cohort (n[27,942) with 15,477, 8495 and 3970 men in CPG1, 2 and 3 respectively. 10-year PCM was 1.0%, 2.2% and 2.7% in CPG1, CPG2 untreated and CPG2 treated men respectively. In contrast, untreated men in CPG3 had a 10-year PCM of 12.5% versus 6.1% in treated men. Thus, men in CPG1&2 consistently had mortality rates <5% regardless of intervention. We next tested using progression to CPG3 as a standardized endpoint for AS. In a well characterized mpMRI based AS cohort (n[133), only 8 men (6%) progressed to CPG3 over a median of 3.5 years. Key diagnostic predictors of progression were a PSA density (PSAd) !0.2 and/or a positive mpMRI scan at diagnosis (!Likert 3). No one with a PSAd <0.2 and negative mpMRI progressed to CPG3. In contrast, the presence of both PSAd !0.2 and positive mpMRI conferred a 27% progression risk. Men with only one of these had an intermediate risk of progression. This identities a 3-tiered surveillance strategy with escalating intensity of out-patient visits, surveillance mpMRI and biopsies informed by individual progression risk.
CONCLUSIONS: Our results suggest that AS can be stratified by prognosis and risk of progression. We propose a 3-tiered follow-up strategy, based on CPG, PSA density and mpMRI, that would reduce out-patient visits, surveillance scans and repeat biopsies. Prospective studies are needed to test whether such risk stratified AS can reduce over-monitoring without compromising safety.
